Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies

Launched by EXELIXIS · Sep 20, 2005

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Histologically confirmed advanced malignancy (solid tumor or lymphoma) that is metastatic or unresectable for which standard curative measures do not exist or are no longer effective
• • Eastern Cooperative Oncology Group (ECOG) performance status \</= 2
• • Life expectancy greater than 3 months
• • Adequate organ and marrow function
• • Written informed consent
• • Use of acceptable methods of contraception during the course of the study and for 3 months after completion of study
• • In the MTD expanded cohort: at least 20 subjects with metastatic and/or advanced/locally recurrent Medullary Thyroid Cancer not appropriate for surgical resection with measurable disease as defined by RECIST
• Exclusion Criteria:
• • Chemotherapy, immunotherapy or radiation within 4 weeks (or nitrosoureas or mitomycin C within 6 weeks) before the first scheduled dose of XL184
• • Administration of an investigational drug within 30 days of the first dose of XL184
• • Subject has not recovered from adverse events due to investigational agents or other medications administered more than 4 weeks before study enrollment
• • Known brain metastases
• • Uncontrolled intercurrent illness
• • Pregnancy or breastfeeding
• • Known HIV positive
• • Known allergy or hypersensitivity to any of the components of the XL184 formulation